Maha FDA: PPE manufacturers directed to test & certify PPE kits in Mumbai-based labs

The Maharashtra Food and Drug Administration (FDA) has directed the PPE manufacturers to test and certify PPE kits in Mumbai-based labs as per Union health ministry guidelines. The Maha FDA has conducted a total of 1945 inspections on personal protective equipment (PPE) kit manufacturers to check the quality of these products till date.

Maharashtra FDA earlier had directed its joint commissioners, assistant commissioners and district level drug control officers to review and oversee the 19 PPE manufacturers in the state for quality compliance. These manufacturers, who have a production capacity ranging from 500 to 15,000 PPE kits daily, are based in Sangli, Pimpri, Nashik, Navi Mumbai, Vasai, Andheri, Mulund, Palghar, Bhiwandi and Bhayander areas of the state.

The Central government had notified EC Order, 2020 to regulate production, quality, distribution and logistics of masks (2ply and 3ply surgical masks, N95 masks) which are part of PPE for COVID-19 management. There are two types of masks which are recommended for various categories of personnel working in hospital or community settings, depending upon the work environment – triple layer medical mask and N-95 respirator mask.

An advisory had also been issued by The Drugs Controller General of India (DCGI) to the PPE manufacturers to voluntarily register under the medical device rules, 2017. The registration will secure the manufacturers a registration number from the CDSCO, which will serve as a quality management system benchmark.

As of today, 107 PPE manufacturers have been approved by the Central Drugs Standard Control Organisation (CDSCO) for supplies in the government healthcare institutions. CDSCO has also directed all approved PPE manufacturers to voluntarily register at its medical device online portal—cdscomdonline.gov.in for quality compliance and to create a database of authentic manufacturers in the country.

  • Related Posts

    Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

    New Delhi: The entry of semaglutide generics in India is ‘stimulating’ market growth and providing a favourable push to Eli Lilly’s blockbuster brand Mounjaro (tirzepatide), said Patrik Jonsson, Executive Vice…

    Pak-made illegal cosmetics recovered from Itwari shop

    Nagpur: Maharashtra Food and Drug Administration (FDA), Nagpur Division, raided a cosmetics firm in Itwari market and seized Pakistan-origin beauty products suspected to have harmful mercury and steroids last week. The…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

    Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

    Pak-made illegal cosmetics recovered from Itwari shop

    Pak-made illegal cosmetics recovered from Itwari shop

    Licences of 20 medical stores suspended after inspections

    Licences of 20 medical stores suspended after inspections

    Bain Capital sells nearly 1 pc stake in Emcure Pharma for Rs 289 crore

    Bain Capital sells nearly 1 pc  stake in Emcure Pharma for Rs 289 crore

    Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

    Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

    HP accounts for 47 inferior drugs in March alert

    HP accounts for 47 inferior drugs in March alert